Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Bioinformatics analysis of single-cell sequencing results
研究概览
简要总结
Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years ≤ age ≤ 75 years.
- •Resectable/borderline resectable pancreatic cancer patients diagnosed based on pathological and preoperative imaging evaluation.
- •No prior history of any form of anti-tumor treatment.
- •At least one measurable lesion.
- •Eastern Cooperative Oncology Group (ECOG): 0-
- •Not participated in any other clinical studies before or during treatment.
- •Willingness to participate voluntarily in this study, signing an informed consent form.
排除标准
- •History of any other malignant tumor, except for completely resected basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, within the past 5 years.
- •Vaccination with live vaccines within 4 weeks prior to enrollment or during the study period.
- •Active autoimmune diseases or a history of autoimmune diseases within the past 4 weeks before enrollment.
- •Allogeneic bone marrow or organ transplantation.
- •Active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors in the gastrointestinal tract, or other conditions determined by the investigator that may cause gastrointestinal bleeding or perforation.
- •Evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding >30 mL within 3 months, hematemesis, melena, or hematochezia), hemoptysis (>5 mL of fresh blood within 4 weeks), or occurrence of thromboembolic events within 12 months (including stroke events and/or transient ischemic attacks).
结局指标
主要结局
Bioinformatics analysis of single-cell sequencing results
时间窗: Collected during surgical treatment
Using single-cell sequencing technology, in-depth analysis of surgical samples from resectable/borderline resectable pancreatic cancer patients is conducted to investigate the composition and interactions of the tumor microenvironment in pancreatic cancer.
次要结局
未报告次要终点
研究者
Yu Pan
Principal Investigator
Fujian Medical University Union Hospital